Key result
Male sex is linked to ~34% higher net adverse event risk versus females in resistant hypertension.
Why the study?
Significant gender differences in blood pressure control and clinical prognosis in patients with resistant hypertension have not been fully revealed.
Does male sex worsen clinical prognosis and blood pressure control compared to female sex in patients with resistant hypertension?
Cohort (n=4,926)
Yes
Does male sex worsen clinical prognosis and blood pressure control compared to female sex in patients with resistant hypertension?
Hazard Ratio: 1.34 (95% CI 1.08–1.67)
Absolute Event Rate: 16% vs 16.6%
In patients with resistant hypertension, men have a higher risk of cardiovascular events and end-organ damage compared to women, suggesting a need for more intensive prevention strategies in males.
Male sex associated with higher net adverse events in resistant hypertension; hypothesis-generating and requires prospective confirmation before practice implications.
BACKGROUND: There are several differences in the clinical course of hypertension due to the biological and social differences between men and women. Resistant hypertension is an advanced disease state, and significant gender difference could be expected, but much has not been revealed yet. The purpose of this study was to compare gender differences on the current status of blood pressure (BP) control and clinical prognosis in patients with resistant hypertension. METHODS: This is a multicenter, retrospective cohort study using common data model databases of 3 tertiary hospitals in Korea. Total 4,926 patients with resistant hypertension were selected from January 2017 to December 2018. Occurrence of dialysis, heart failure (HF) hospitalization, myocardial infarction, stroke, dementia or all-cause mortality was followed up for 3 years. RESULTS: Male patients with resistant hypertension were younger but had a higher cardiovascular risk than female patients. Prevalence of left ventricular hypertrophy and proteinuria was higher in men than in women. On-treatment diastolic BP was lower in women than in men and target BP achievement rate was higher in women than in men. During 3 years, the incidence of dialysis and myocardial infarction was higher in men, and the incidence of stroke and dementia was higher in women. After adjustment, male sex was an independent risk factor for HF hospitalization, myocardial infarction, and all-cause death. CONCLUSION: In resistant hypertension, men were younger than women, but end-organ damage was more common and the risk of cardiovascular event was higher. More intensive cardiovascular prevention strategies may be required in male patients with resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Joo et al. (2023) conducted a cohort in Resistant hypertension (n=4,926). Male sex vs. Female sex was evaluated on Net adverse events (composite of all-cause death, dementia, stroke, myocardial infarction, heart failure hospitalization, and dialysis) (HR 1.34, 95% CI 1.08-1.67). In patients with resistant hypertension, male sex was an independent risk factor for net adverse events compared to female sex (adjusted HR 1.34) over a 3-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: